Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?

Mahmoud Abdelnabi; Abdallah Almaghraby; Yehia Saleh

doi:10.15420/ecr.2019.1.3

Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?

Eur Cardiol. 2020 Feb 26:15:1-2. doi: 10.15420/ecr.2019.1.3. eCollection 2020 Feb.

Authors

Mahmoud Abdelnabi¹, Abdallah Almaghraby², Yehia Saleh^{2

3}

Affiliations

¹ Cardiology and Angiology Unit, Department of Clinical and Experimental Internal Medicine, Medical Research Institute, University of Alexandria, Egypt.
² Department of Cardiology, Faculty of Medicine, University of Alexandria, Egypt.
³ Michigan State University, East Lansing, MI, US.

Abstract

Although there are abundant data highlighting the safety and efficacy of direct oral anticoagulants, to date, recent guidelines have limited their use to stroke prevention in patients with non-valvular AF, as well as in the prevention and treatment of venous thromboembolism and pulmonary embolism. Encouraging data about the off-label use of direct oral anticoagulants have been shown in several other indications, such as intracardiac thrombi, left ventricular thrombi and left atrial appendage, but a large sector of patients are still not addressed, such as valvular and prosthetic patients.

Keywords: Prosthetic valves; direct oral anticoagulants; left ventricular thrombi; rivaroxaban; vitamin K antagonist.

Publication types

Review